Synairgen (LON:SNG) Stock Price Down 0.2% – Here’s What Happened

Posted by Stephan Jacobs on Jan 20th, 2025

Synairgen plc (LON:SNG – Get Free Report) traded down 0.2% during trading on Monday . The company traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02). 478,281 shares changed hands during trading, a decline of 82% from the average session volume of 2,614,922 shares. The stock had previously closed at GBX 2 ($0.02).

Synairgen Stock Down 12.3 %

The business’s 50 day simple moving average is GBX 3.56 and its 200-day simple moving average is GBX 3.94. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The company has a market cap of £3.53 million, a price-to-earnings ratio of -58.50 and a beta of -2.23.

Synairgen Company Profile

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).